A Phase 1 interventional study of Levetiracetam and Levetiracetam in Healthy Volunteers, sponsored by UCB Pharma. Completed at 1 site in United Kingdom. Open to participants aged 20 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2011-10-06.
Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to investigate the pharmacokinetics(PK) and evaluate the bioequivalence of levetiracetam (LEV) following a single 15-minutes IV infusion of 1500 mg and a single oral dose(tablets) of 1500 mg in healthy Japanese subjects.
UCB Pharma is the lead sponsor of 242 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Levetiracetam
Drug: Levetiracetam
Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
Also known as: E-Keppra
Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
Also known as: E-Keppra
Maximum drug concentration (Cmax)
Time frame: Multiple sampling from 0 to 36 hours following single dose
Area under the plasma drug concentration versus time curve from hour 0 to the time with a last quantifiable level (AUCo-t)
Time frame: Multiple sampling from 0 to 36 hours (could be less than 36 hours if the last quantifiable concentration is below limit of quantification), following single dose
Time to reach maximum plasma concentration (tmax)
Time frame: Multiple sampling from 0 to 36 hours following single dose
Plasma concentration at the end of infusion (C15' )
Time frame: At 15 minutes after termination of the15-minutes infusion
Area under the curve from 0 to infinity (AUC)
Time frame: Multiple sampling from 0 to 36 hours following single dose
Mean resident time (MRT)
Time frame: Multiple sampling from 0 to 36 hours following single dose
Terminal elimination half-life(t1/2)
Time frame: Multiple sampling from 0 to 36 hours following single dose
First order terminal elimination rate constant (λz )
Time frame: Multiple sampling from 0 to 36 hours following single dose
Total body clearance after oral administration (CL/F) or after IV infusion (CL)
Time frame: Multiple sampling from 0 to 36 hours following single dose
Volume of distribution after oral administration(Vz/F) or after IV infusion(Vz)
Time frame: Multiple sampling from 0 to 36 hours following single dose
The record gives a start of Jun 2011, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Levetiracetam